Q2 EPS Estimates for Pharming Group Decreased by Analyst

Pharming Group (NASDAQ:PHAR - Free Report) - HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for shares of Pharming Group in a research note issued on Thursday, May 8th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.20) for the quarter, down from their previous forecast of ($0.14). HC Wainwright currently has a "Buy" rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group's Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.60 EPS.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The business had revenue of $79.09 million for the quarter, compared to the consensus estimate of $67.74 million.

Separately, Oppenheimer lifted their target price on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.

Pharming Group Stock Performance

PHAR traded down $0.02 on Monday, reaching $9.11. The company had a trading volume of 581 shares, compared to its average volume of 6,505. The stock has a market cap of $619.76 million, a P/E ratio of -35.04 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $11.07. The company's fifty day moving average is $8.59 and its 200 day moving average is $8.74.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.